AI Tokens
Stock Analysis on Net

Shockwave Medical Inc. (NASDAQ:SWAV)

This company has been moved to the archive! The financial data has not been updated since May 6, 2024.

Analysis of Profitability Ratios

Microsoft Excel

Profitability Ratios (Summary)

Return on Sales

Return on Investment

Shockwave Medical Inc., profitability ratios

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Return on Sales
Gross profit margin 86.94% 86.73% 82.53% 69.03% 60.03%
Operating profit margin 21.79% 25.35% -0.37% -96.86% -120.76%
Net profit margin 20.17% 44.10% -3.85% -96.92% -119.06%
Return on Investment
Return on equity (ROE) 22.03% 42.24% -3.78% -29.11% -26.53%
Return on assets (ROA) 9.40% 33.43% -2.64% -24.15% -22.04%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).


A comprehensive transition from a high-loss growth phase to a sustainable profitable state is evident between 2019 and 2023. The financial trajectory is marked by a consistent expansion of gross margins and a definitive pivot toward positive net earnings and returns on capital starting in 2022.

Margin Expansion and Operational Efficiency
Gross profit margin demonstrated a steady and significant upward trend, rising from 60.03% in 2019 to 86.94% by 2023. This consistent growth suggests improved pricing power or a reduction in the cost of goods sold relative to revenue.
Profitability Pivot
Operating and net profit margins shifted from severe deficits to positive territory. Operating profit margin improved from -120.76% in 2019 to 21.79% in 2023, while net profit margin moved from -119.06% to 20.17% over the same period. A notable peak in net profitability occurred in 2022 at 44.10% before normalizing in 2023.
Returns on Investment
Return on Equity (ROE) and Return on Assets (ROA) mirrored the overall profitability trend. Both ratios remained negative through 2021, indicating a period of capital consumption. A sharp reversal occurred in 2022, with ROE reaching 42.24% and ROA reaching 33.43%. By 2023, these figures moderated to 22.03% and 9.40%, respectively, while remaining positive.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Gross Profit Margin

Shockwave Medical Inc., gross profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in thousands)
Gross profit 634,842 424,737 195,708 46,798 25,768
Revenue 730,230 489,733 237,146 67,789 42,927
Profitability Ratio
Gross profit margin1 86.94% 86.73% 82.53% 69.03% 60.03%
Benchmarks
Gross Profit Margin, Competitors2
Abbott Laboratories 50.28% 51.54% 52.21% — —
Elevance Health Inc. 16.79% 16.79% 17.09% — —
Intuitive Surgical Inc. 66.39% 67.44% 69.32% — —
Medtronic PLC 65.67% 67.98% 65.19% — —
UnitedHealth Group Inc. 23.64% 24.09% 23.60% — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Gross profit margin = 100 × Gross profit ÷ Revenue
= 100 × 634,842 ÷ 730,230 = 86.94%

2 Click competitor name to see calculations.


Analysis of the five-year period from 2019 to 2023 reveals a period of aggressive expansion and substantial improvement in operational profitability. The simultaneous increase in total revenue and the widening of gross margins indicate strong operational leverage and an enhanced ability to manage the cost of goods sold relative to sales growth.

Revenue and Gross Profit Trajectory
Revenue grew from 42,927 thousand USD in 2019 to 730,230 thousand USD in 2023. This scale-up was accompanied by a corresponding surge in gross profit, which rose from 25,768 thousand USD to 634,842 thousand USD. The most rapid acceleration occurred between 2020 and 2022, during which revenue increased more than seven-fold.
Gross Profit Margin Expansion
A significant upward trend in the gross profit margin is observed, moving from 60.03% in 2019 to 86.94% in 2023. The most substantial growth occurred between 2020 and 2021, where the margin increased by 13.5 percentage points. Such a trajectory suggests a successful shift in product mix, increased pricing power, or significant economies of scale in production.
Margin Stabilization
Following a period of rapid expansion, the gross profit margin reached a plateau between 2022 and 2023. The margin shifted from 86.73% to 86.94%, indicating that the gains in production efficiency and pricing optimization have stabilized at a high level of profitability.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Operating Profit Margin

Shockwave Medical Inc., operating profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in thousands)
Income (loss) from operations 159,093 124,134 (871) (65,663) (51,839)
Revenue 730,230 489,733 237,146 67,789 42,927
Profitability Ratio
Operating profit margin1 21.79% 25.35% -0.37% -96.86% -120.76%
Benchmarks
Operating Profit Margin, Competitors2
Abbott Laboratories 16.15% 19.16% 19.56% — —
Elevance Health Inc. 4.47% 4.94% 5.15% — —
Intuitive Surgical Inc. 24.80% 25.35% 31.89% — —
Medtronic PLC 17.56% 18.15% 14.89% — —
UnitedHealth Group Inc. 8.80% 8.83% 8.40% — —
Operating Profit Margin, Sector
Health Care Equipment & Services 8.71% 9.26% 9.13% — —
Operating Profit Margin, Industry
Health Care 12.79% 18.74% 18.04% — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Operating profit margin = 100 × Income (loss) from operations ÷ Revenue
= 100 × 159,093 ÷ 730,230 = 21.79%

2 Click competitor name to see calculations.


The operating profit margin exhibited a significant and positive trend over the observed period. Initially, the company experienced substantial operating losses, resulting in a negative operating profit margin. However, subsequent years demonstrate a clear progression towards profitability.

Operating Profit Margin Trend
In 2019 and 2020, the operating profit margin was significantly negative, registering at -120.76% and -96.86% respectively. This indicates substantial operating losses relative to revenue. A considerable improvement is then observed in 2021, with the margin moving to -0.37%, signifying a near-breakeven operating performance.
The year 2022 marked a turning point, as the operating profit margin became positive, reaching 25.35%. This represents a substantial increase in profitability from operations. While remaining positive, the operating profit margin experienced a slight decrease in 2023, settling at 21.79%. Despite this decrease, the 2023 margin still demonstrates a strong level of operating profitability.

The progression from large operating losses to positive and substantial operating profit margins suggests successful implementation of strategies to improve operational efficiency and/or increase revenue. The slight decline in the operating profit margin from 2022 to 2023 warrants further investigation to determine the underlying causes, such as increased operating expenses or changes in revenue mix.

Relationship to Revenue
The improvement in the operating profit margin correlates with a substantial increase in revenue. Revenue grew from US$42,927 thousand in 2019 to US$730,230 thousand in 2023. This revenue growth likely contributed significantly to the company’s ability to achieve operating profitability.
The initial operating losses, despite increasing revenue from 2019 to 2020, suggest that operating expenses were growing at a faster rate than revenue. The subsequent improvement in the operating profit margin indicates that expense growth was brought under control, allowing the company to leverage revenue growth into profitability.

Overall, the operating profit margin demonstrates a compelling narrative of improvement, transitioning from significant losses to robust profitability alongside substantial revenue growth.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Net Profit Margin

Shockwave Medical Inc., net profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in thousands)
Net income (loss) 147,278 215,996 (9,136) (65,699) (51,109)
Revenue 730,230 489,733 237,146 67,789 42,927
Profitability Ratio
Net profit margin1 20.17% 44.10% -3.85% -96.92% -119.06%
Benchmarks
Net Profit Margin, Competitors2
Abbott Laboratories 14.27% 15.88% 16.42% — —
Elevance Health Inc. 3.52% 3.87% 4.46% — —
Intuitive Surgical Inc. 25.24% 21.25% 29.85% — —
Medtronic PLC 12.03% 15.90% 11.97% — —
UnitedHealth Group Inc. 6.09% 6.25% 6.06% — —
Net Profit Margin, Sector
Health Care Equipment & Services 6.43% 7.05% 7.14% — —
Net Profit Margin, Industry
Health Care 11.49% 14.65% 15.24% — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Net profit margin = 100 × Net income (loss) ÷ Revenue
= 100 × 147,278 ÷ 730,230 = 20.17%

2 Click competitor name to see calculations.


The net profit margin exhibited significant fluctuations over the five-year period. Initially, the company experienced substantial negative net profit margins, which progressively improved, culminating in positive and then stabilizing margins.

Net Profit Margin Trend
In 2019 and 2020, the net profit margin was significantly negative, registering at -119.06% and -96.92% respectively. This indicates substantial net losses relative to revenue during these years. A considerable improvement is observed in 2021, with the net profit margin increasing to -3.85%, suggesting a reduction in the magnitude of net losses.
A dramatic shift occurred in 2022, as the net profit margin turned positive, reaching 44.10%. This represents a substantial increase in profitability. While the margin decreased in 2023 to 20.17%, it remained positive and indicated continued profitability, albeit at a lower rate than the previous year.

The progression from large negative margins to a positive, though fluctuating, margin suggests a significant change in the company’s operational efficiency and/or revenue generation capabilities. The substantial increase in revenue, coupled with the eventual achievement of positive net income, drove the improvement in the net profit margin. The decrease from 44.10% to 20.17% between 2022 and 2023 warrants further investigation to determine the underlying factors, such as increased costs or a slower growth rate in net income compared to revenue.

Relationship to Revenue
The net profit margin’s improvement closely correlates with the growth in revenue. Revenue increased steadily from US$42,927 thousand in 2019 to US$730,230 thousand in 2023. The ability to translate this revenue growth into positive net income, as evidenced by the margin’s trajectory, is a positive indicator.

Overall, the net profit margin demonstrates a clear trend of improvement, transitioning from significant losses to consistent profitability. However, the recent decrease in margin from 2022 to 2023 suggests a need for continued monitoring and analysis of the factors influencing profitability.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Return on Equity (ROE)

Shockwave Medical Inc., ROE calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in thousands)
Net income (loss) 147,278 215,996 (9,136) (65,699) (51,109)
Stockholders’ equity 668,677 511,316 241,830 225,654 192,653
Profitability Ratio
ROE1 22.03% 42.24% -3.78% -29.11% -26.53%
Benchmarks
ROE, Competitors2
Abbott Laboratories 14.83% 18.90% 19.75% — —
Elevance Health Inc. 15.23% 16.59% 16.93% — —
Intuitive Surgical Inc. 13.51% 11.98% 14.32% — —
Medtronic PLC 7.30% 9.59% 7.01% — —
UnitedHealth Group Inc. 25.22% 25.87% 24.09% — —
ROE, Sector
Health Care Equipment & Services 17.13% 18.40% 17.28% — —
ROE, Industry
Health Care 19.40% 24.82% 25.44% — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
ROE = 100 × Net income (loss) ÷ Stockholders’ equity
= 100 × 147,278 ÷ 668,677 = 22.03%

2 Click competitor name to see calculations.


The Return on Equity (ROE) exhibited significant fluctuations over the observed period. Initially negative, the ROE transitioned to positive values, demonstrating a substantial improvement in profitability relative to shareholder equity.

Net Income Trend
Net income moved from substantial losses in 2019 and 2020, totaling approximately US$51.1 million and US$65.7 million respectively, to a loss of US$9.1 million in 2021. A significant turnaround occurred in 2022, with net income reaching US$216.0 million, followed by US$147.3 million in 2023. This positive trend in net income is a primary driver of the ROE improvement.
Stockholders’ Equity Trend
Stockholders’ equity consistently increased throughout the period, rising from US$192.7 million in 2019 to US$668.7 million in 2023. The most substantial increase occurred between 2021 and 2022, growing from US$241.8 million to US$511.3 million. This growth in equity provides a larger base against which to measure returns.
ROE Analysis
The ROE was negative in 2019 and 2020, at -26.53% and -29.11% respectively, reflecting the net losses experienced during those years. In 2021, the ROE remained negative, albeit reduced to -3.78%, indicating a lessening of losses. A dramatic increase was observed in 2022, with the ROE reaching 42.24%, driven by the significant improvement in net income and a substantial increase in stockholders’ equity. While still positive, the ROE decreased to 22.03% in 2023, likely due to a decrease in net income compared to 2022, despite continued growth in equity.

The substantial improvement in ROE from negative values to over 40% suggests a significant positive shift in the company’s ability to generate profits from shareholder investments. The subsequent decrease in ROE in 2023, while remaining positive, warrants further investigation to determine the underlying causes and potential implications for future performance.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Return on Assets (ROA)

Shockwave Medical Inc., ROA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in thousands)
Net income (loss) 147,278 215,996 (9,136) (65,699) (51,109)
Total assets 1,566,563 646,089 345,682 272,042 231,938
Profitability Ratio
ROA1 9.40% 33.43% -2.64% -24.15% -22.04%
Benchmarks
ROA, Competitors2
Abbott Laboratories 7.82% 9.31% 9.40% — —
Elevance Health Inc. 5.50% 5.86% 6.26% — —
Intuitive Surgical Inc. 11.64% 10.19% 12.58% — —
Medtronic PLC 4.13% 5.54% 3.87% — —
UnitedHealth Group Inc. 8.18% 8.19% 8.15% — —
ROA, Sector
Health Care Equipment & Services 7.05% 7.49% 7.28% — —
ROA, Industry
Health Care 7.19% 9.66% 9.46% — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
ROA = 100 × Net income (loss) ÷ Total assets
= 100 × 147,278 ÷ 1,566,563 = 9.40%

2 Click competitor name to see calculations.


The Return on Assets (ROA) exhibited a significant trajectory over the observed period. Initially negative, the ratio transitioned to positive values, demonstrating improving profitability relative to asset utilization. The magnitude of change increased substantially from 2019 through 2023.

ROA Trend (2019-2023)
From 2019 to 2020, ROA declined from -22.04% to -24.15%, indicating a worsening of profitability in relation to assets. This period reflects increasing losses against a growing asset base.
A modest improvement occurred in 2021, with ROA reaching -2.64%. While still negative, this suggests a reduction in losses and/or more efficient asset utilization compared to the prior two years.
2022 witnessed a dramatic positive shift, with ROA surging to 33.43%. This substantial increase is attributable to a significant rise in net income alongside continued asset growth.
In 2023, ROA moderated to 9.40%. While still positive, this represents a considerable decrease from the prior year, likely due to a slower growth rate in net income relative to the substantial increase in total assets.

The progression from consistent losses to positive, albeit fluctuating, returns suggests a potential turning point in the company’s operational efficiency and profitability. However, the decline in ROA in the most recent year warrants further investigation to determine the sustainability of profitability gains given the expanding asset base.

Net Income and ROA Relationship
The ROA figures closely mirror the trend in net income. Negative net income in the earlier years directly resulted in negative ROA values. The substantial increase in net income in 2022 was the primary driver of the corresponding increase in ROA.
The comparatively smaller increase in net income in 2023, coupled with a large increase in total assets, explains the decrease in ROA observed during that period.

The company’s ability to effectively deploy its growing asset base will be crucial in maintaining and improving ROA in future periods.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?